Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Overview
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Companies Involved in Therapeutics Development
Bayer AG
FibroGen Inc
GlaxoSmithKline Plc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Drug Profiles
daprodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDO-3055 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molidustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roxadustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0463518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Dormant Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Discontinued Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Product Development Milestones
Featured News & Press Releases
Dec 02, 2019: FibroGen announces Roxadustat inclusion in Chi’s tiol Reimbursement Drug List
Nov 29, 2019: JT Files New Drug Application of Erodustat(JTZ-951),for the treatment of Anemia Associated with CKD in Japan
Nov 08, 2019: Roxadustat phase III program pooled alyses showed positive efficacy and no increased cardiovascular risk in patients with anemia from chronic kidney disease versus comparators
Nov 08, 2019: AstraZeneca reports positive Phase III data for roxadustat
Oct 30, 2019: AstraZeneca to present pivotal roxadustat phase III data at the American Society of Nephrology Kidney Week 2019
Oct 11, 2019: Roxadustat global phase 3 results for treatment of chronic kidney disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019
Sep 30, 2019: FibroGen receives one of Chi Pharmaceutical Industrys highest awards for clinical innovation for Roxadustat
Sep 26, 2019: FibroGen announces initiation of phase 2 clinical trial of Roxadustat for the treatment of anemia in cancer patients receiving chemotherapy
Sep 20, 2019: Roxadustat approved in Japan for the treatment of anemia associated with Chronic Kidney Disease in Dialysis Patients
Aug 23, 2019: GSK files daprodustat’s first regulatory submission in Japan
Aug 21, 2019: Roxadustat Approved in Chi for Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis
Jul 24, 2019: The New England Jourl of Medicine (NEJM) publishes Roxadustat Chi phase 3 results for the treatment of anemia in chronic kidney disease patients receiving dialysis
Jul 24, 2019: Roxadustat Chi phase 3 trial for treatment of anemia in chronic kidney disease patients not on dialysis published in the New England Jourl of Medicine (NEJM)
Jul 12, 2019: Top-line Results of Phase 3 Clinical Studies of JTZ-951 (erodustat), in Anemic Patients with Chronic Kidney Disease (Comparative Study) in Japan
May 09, 2019: FibroGen roxadustat announces positive topline results from pooled safety alyses of roxadustat global Phase 3 program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by FibroGen Inc, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Japan Tobacco Inc, H2 2019
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019